BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
05/22/2018
Initial Lawsuit
10/25/2018
Lawsuit Progression
11/01/2019
Settlement
06/26/2020
Investors investigation regarding Dycom’s dependency on permitting and tactical considerations, related margin pressure and absorption issues, reduced guidance on contract revenues and diluted earnings per shares (diluted EPS).
05/22/2018
Dycom releases its Q1 2018 financial results, revising its financial guidance for the 2019 fiscal year to “reflect the actual results for the quarter ended April 28, 2018 and the anticipated timing of activity on large customer programs and the related impacts on revenues and margins.” During the related conference call Dycom’s chief financial officer (CFO) DeFerrari explained the “disappointing” margin pressure by “the under-absorption of labor and field costs as large customer programs mobilized.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$92.64 | $116.20 | $-23.56 | -20.27% |
This securities class action lawsuit is filed on behalf of “all investors who purchased or otherwise acquired Dycom common stock between November 20, 2017, and August 10, 2018, inclusive.”
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) Dycom’s large projects were highly dependent on permitting and tactical considerations;
(ii) Dycom was facing great uncertainties related to permitting issues;
(iii) said uncertainties would expose Dycom to near-term margin pressure and absorption issues; and
(iv) as a result of the foregoing, defendants’ statements about Dycom’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
11/01/2019
The court issued an order appointing the lead plaintiff and lead counsel.
03/13/2019
Lead Plaintiff brings this action against Dycom Industries, Inc., Chief Executive Officer Steven Nielsen, and Chief Financial Officer Andrew DeFerrari on behalf of itself and all other persons similarly situated who purchased or otherwise acquired Dycom common stock between November 20, 2017 and August 10, 2018, inclusive (the “Class Period”), and were damaged thereby.
Operative complaint
04/19/2019
A motion to dismiss was filed with the court.
04/14/2020
Court Denied the motion to dismiss.
On 06/26/2020, lead counsel Labaton Sucharow LLP, Levi & Korsinsky, LLP, Thornton Law Firm LLP announced a proposed class action settlement.
The court preliminarily approved the settlement on 07/09/2020. The settlement has a total value of $9,500,000 in Cash.
The notice states that you may be included, if you purchased or otherwise acquired the company’s publicly traded common stock during the period from 11/20/2017 to 08/10/2018, inclusive.
According to the notice, the estimated average cash recovery per damaged share of common stock will be approximately $0.88 per share, before deduction of court-approved fees and expenses. Lead Counsel filed a motion for an award of attorneys’ fees not to exceed 29% of the $9,500,000 and payment of expenses not to exceed $350,000.
For information purposes only, last updated on 07/23/2020. Contact the claims administrator or lead counsel for further information.
On 10/13/2020, the court awarded lead counsel fees and reimbursement of expenses. The court acknowledged 2,550 hours, with a lodestar value of $1,863,660.25, spent by lead counsel to achieve the settlement. The court awarded attorney fees of 29% of the total value of settlement (or $2,755,000) plus litigation expenses of $98,028.19.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.